Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GT-GBA1-S05 is a preclinical ex vivo hematopoietic stem cell gene therapy being developed by Glafabra Therapeutics for the treatment of Gaucher disease. Utilizing the proprietary Live-cel platform, the therapy involves harvesting a patient's own hematopoietic stem cells and genetically modifying them using lentiviral vectors to carry a functional copy of the GBA1 gene. Once reinfused, these engineered cells engraft in the bone marrow and differentiate into various blood cell lineages that provide a continuous source of the glucocerebrosidase (GBA) enzyme throughout the body via a mechanism known as cross-correction. This one-time treatment is designed to restore enzyme activity and provide a durable therapeutic alternative to traditional enzyme replacement therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GT-GBA1-S05.